Background. Male patients with oral and oropharyngeal cancer are known to have high risk of concomitant esophageal cancer developing. Thus, mass screening programs are pursued to detect such esophageal cancer early, and in a mass screening trial of patients with early oral and oropharyngeal cancer, the efficacy of Lugol dye endoscopy for detecting concomitant esophageal cancers has been evaluated.
Methods. Lugol dye was used in an endoscopic screening of 101 patients with oral cancer and 26 with oropharyngeal cancer; all of the patients were men.
Results. Among these 127 patients, eight (6.3%) clinical asymptomatic concomitant esophageal cancers were detected, and four of these eight cancers were found in the patients with oropharyngeal cancer. Five of these eight superficial lesions could not be detected by ordinary endoscopy or barium study.
Conclusion. Our results show that Lugol dye endoscopy is indispensable for monitoring male patients with oral or oropharyngeal cancer to detect an early concomitant esophageal cancer. In addition, a higher frequency of concomitant esophageal cancer was seen in the patients with oropharyngeal cancer than in the patients with oral cancer. Cancer 1994; 73:2038–41.
We compared the growth rate of locally recurrent hepatocellular carcinoma (HCC) with that of primary HCC. After the first treatment by transcatheter arterial chemoembolization (TACE), 60 locally recurrent HCC nodules were reviewed. The tumor volume doubling time (DT) of locally recurrent HCC was significantly shorter than that of primary HCC. The 95% lower threshold value was 17.7 days. The 6-, 12-, and 36-month recurrence-free rates of the tumors having DTs more than 70 days after the second TACE (77.7%, 53.8%, and 40.4%) were significantly higher than those of the tumors having DTs less than 70 days (26.7%, 26.7%, and 17.8%). Locally recurrent HCCs cannot double in diameter in less than 53 days. In the case that an equivocal lesion smaller than the section collimation depicted during a contrast-enhanced computed tomography (CECT) screening cannot be ruled out as local recurrence, the next CECT screening should be performed 2 months later.
The line that extends beyond the middle or right hepatic vein from the inferior vena cava does not coincide with the main or right longitudinal scissura on axial images of the upper portion of the liver.
Local therapeutic results of single new lesions were better than those of multiple new lesions, and the local therapeutic effect of TACE was not affected by the number of treatments on the basis of patient, tumor location, or tumor size.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.